Pharmacokinetics of Ammoxetine Hydrochloride in Participants With Moderate Renal Impairment and Normal Renal Function

Phase 1, open-label trial of ammoxetine in major depressive disorder (MDD) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Area under the concentration vs. time curve for one dosing interval at steady-state at 96 hours and Maximum concentration observed during dosing interval at steady-state at 96 hours. Started May 2026; status: recruiting.